BBIO
Price
$42.79
Change
-$0.39 (-0.90%)
Updated
Jul 1, 04:59 PM (EDT)
Capitalization
8.2B
30 days until earnings call
TRVI
Price
$5.70
Change
+$0.23 (+4.20%)
Updated
Jul 1, 02:56 PM (EDT)
Capitalization
666M
37 days until earnings call
Interact to see
Advertisement

BBIO vs TRVI

Header iconBBIO vs TRVI Comparison
Open Charts BBIO vs TRVIBanner chart's image
BridgeBio Pharma
Price$42.79
Change-$0.39 (-0.90%)
Volume$26.44K
Capitalization8.2B
Trevi Therapeutics
Price$5.70
Change+$0.23 (+4.20%)
Volume$3.11K
Capitalization666M
BBIO vs TRVI Comparison Chart in %
Loading...
BBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BBIO vs. TRVI commentary
Jul 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BBIO is a Hold and TRVI is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 01, 2025
Stock price -- (BBIO: $43.18 vs. TRVI: $5.47)
Brand notoriety: BBIO and TRVI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BBIO: 167% vs. TRVI: 81%
Market capitalization -- BBIO: $8.2B vs. TRVI: $666M
BBIO [@Biotechnology] is valued at $8.2B. TRVI’s [@Biotechnology] market capitalization is $666M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BBIO’s FA Score shows that 1 FA rating(s) are green whileTRVI’s FA Score has 0 green FA rating(s).

  • BBIO’s FA Score: 1 green, 4 red.
  • TRVI’s FA Score: 0 green, 5 red.
According to our system of comparison, BBIO is a better buy in the long-term than TRVI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BBIO’s TA Score shows that 6 TA indicator(s) are bullish while TRVI’s TA Score has 3 bullish TA indicator(s).

  • BBIO’s TA Score: 6 bullish, 4 bearish.
  • TRVI’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, BBIO is a better buy in the short-term than TRVI.

Price Growth

BBIO (@Biotechnology) experienced а +2.38% price change this week, while TRVI (@Biotechnology) price change was -4.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.51%. For the same industry, the average monthly price growth was +32.88%, and the average quarterly price growth was +3.93%.

Reported Earning Dates

BBIO is expected to report earnings on Jul 31, 2025.

TRVI is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (-0.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BBIO($8.2B) has a higher market cap than TRVI($666M). BBIO YTD gains are higher at: 57.362 vs. TRVI (32.767). TRVI has higher annual earnings (EBITDA): -47.23M vs. BBIO (-551.92M). BBIO has more cash in the bank: 541M vs. TRVI (103M). TRVI has less debt than BBIO: TRVI (957K) vs BBIO (1.86B). BBIO has higher revenues than TRVI: BBIO (127M) vs TRVI (0).
BBIOTRVIBBIO / TRVI
Capitalization8.2B666M1,231%
EBITDA-551.92M-47.23M1,169%
Gain YTD57.36232.767175%
P/E RatioN/AN/A-
Revenue127M0-
Total Cash541M103M525%
Total Debt1.86B957K194,148%
FUNDAMENTALS RATINGS
BBIO vs TRVI: Fundamental Ratings
BBIO
TRVI
OUTLOOK RATING
1..100
2157
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
55
Fair valued
PROFIT vs RISK RATING
1..100
7978
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
3647
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BBIO's Valuation (4) in the null industry is somewhat better than the same rating for TRVI (55) in the Pharmaceuticals Major industry. This means that BBIO’s stock grew somewhat faster than TRVI’s over the last 12 months.

TRVI's Profit vs Risk Rating (78) in the Pharmaceuticals Major industry is in the same range as BBIO (79) in the null industry. This means that TRVI’s stock grew similarly to BBIO’s over the last 12 months.

TRVI's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as BBIO (99) in the null industry. This means that TRVI’s stock grew similarly to BBIO’s over the last 12 months.

BBIO's Price Growth Rating (36) in the null industry is in the same range as TRVI (47) in the Pharmaceuticals Major industry. This means that BBIO’s stock grew similarly to TRVI’s over the last 12 months.

BBIO's P/E Growth Rating (100) in the null industry is in the same range as TRVI (100) in the Pharmaceuticals Major industry. This means that BBIO’s stock grew similarly to TRVI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BBIOTRVI
RSI
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 9 days ago
78%
Bullish Trend 26 days ago
81%
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
BBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RGSAX35.04N/A
N/A
Virtus KAR Global Small-Cap A
PCLVX21.98N/A
N/A
PACE Large Co Value Equity P
SUVCX10.60N/A
N/A
PGIM Quant Solutions Large-Cap Val C
HBLRX14.71N/A
N/A
Hartford Balanced Income R3
FSLZX46.54N/A
N/A
Fidelity Advisor Stock Selec Mid Cp Z

BBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, BBIO has been loosely correlated with ROIV. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if BBIO jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BBIO
1D Price
Change %
BBIO100%
-3.74%
ROIV - BBIO
45%
Loosely correlated
-1.05%
AXON - BBIO
44%
Loosely correlated
+1.14%
ARRY - BBIO
43%
Loosely correlated
-8.39%
XENE - BBIO
43%
Loosely correlated
-3.40%
PMN - BBIO
43%
Loosely correlated
+0.75%
More

TRVI and

Correlation & Price change

A.I.dvisor indicates that over the last year, TRVI has been loosely correlated with PTGX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if TRVI jumps, then PTGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRVI
1D Price
Change %
TRVI100%
-2.67%
PTGX - TRVI
44%
Loosely correlated
-0.75%
BIESF - TRVI
42%
Loosely correlated
N/A
GOSS - TRVI
31%
Poorly correlated
-1.60%
MLYS - TRVI
31%
Poorly correlated
-1.31%
QURE - TRVI
30%
Poorly correlated
+0.43%
More